Company: APM
Filing Date: 2025-07-15
Form Type: DRS
Source: 0001213900-25-063899
Chunk: 140

Company: Aptorum Group Ltd
Filing Date: 2025-07-15
Form: DRS
Chunk 140
---
 capital beyond the near term. If DiamiR is unable to raise capital when needed, its business, financial condition and results
of operations would be materially adversely affected, and it could be forced to reduce or discontinue its operations.

If DiamiR borrows money to expand its business, the likelihood that investors may lose some or all of their investment may increase.

DiamiR anticipates that it
may incur debt for financing its growth. DiamiR’s ability to borrow funds will depend upon a number of factors, including the condition
of the financial markets. If DiamiR receives debt financing, it will have priority in any liquidation over the claims of holders of its
stockholders, which could increase the risk of loss of your investment. In addition, DiamiR’s payment obligations with respect to
any indebtedness could divert funds away from its operations, marketing and product development efforts.

The ongoing uncertainty in global economic conditions may negatively impact DiamiR’s business, operating results or financial condition.

The continuing unfavorable
global economic conditions and uncertainty have caused a general tightening in the credit markets, lower levels of liquidity, increases
in the rates of default and bankruptcy and extreme volatility in credit, equity and fixed income markets. These macroeconomic conditions
could negatively affect DiamiR’s business, operating results or financial condition in a number of ways. For example, potential
future clients may be unable to fund purchases of products and services, which could cause them to delay, decrease or cancel purchases
of DiamiR’s products and services or to not pay DiamiR or to delay paying DiamiR for previously purchased products and services.
DiamiR’s clients may cease business operations or conduct business on a greatly reduced basis.

<div align='center'>65</div>

DiamiR faces significant, evolving competition which, if it fails to properly address, could adversely affect its business, results of operations, and financial condition.

The markets for molecular
diagnostics are intensely competitive, and DiamiR faces significant competition from a number of different sources. Several of DiamiR’s
competitors have substantially greater name recognition and financial, technical, product development and marketing resources than DiamiR
does. There has been significant merger and acquisition activity among a number of its competitors in recent years. Transaction induced
pressures, or other related factors may result in negative market dynamics that could adversely affect DiamiR’s business, results
of operations and financial condition.

DiamiR competes in all of
its markets with